Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Fiber is something most people could use more of. But experts advise caution with 'fibermaxxing' - 2Discussion on deployment of foreign troops ongoing, two sources tell 'Post'
- 3Dolly Parton misses Dollywood event due to 'a few health challenges' after skipping honorary Oscars
- 4One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- 5Why screening for the deadliest cancer in the U.S. misses most cases
- 6 Financial plan 3D Printers with the Best Worth
- Instructions to Grasp the Innovation Behind 5G Pinnacles\
- Geminid shooting stars: One of 2025's most exciting meteor showers begins tonight
- The Best Cell phone Brands for Tech Lovers
- A somber Thor is returning for 'Avengers: Doomsday': Watch the dread-filled teaser
- Pfizer in $41.5 million settlement with Texas over ADHD drug for children
- 5 Great Home Remodel Administrations With Green Arrangements In 2024
- Israeli archaeologists launch project to trace origins of ancient pottery
- Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
